Condition: Sickle Cell Disease · Sponsor: National Human Genome Research Institute (NHGRI)
The purpose of this research study is to look at genes and determine how they interact with each other to find changes that could explain why some people's immune systems may respond to blood transfusions. This response is called an alloimmune response. We strongly believe that when someone has an alloimmune response, it is caused by changes in their genes. We plan to compare changes in the genes of individuals that develop red blood cell alloimmunization after blood transfusions with those that do not develop alloimmunization. This may help us to create more targeted therapeutic interventions, which may improve the health of alloimmune responders.
This description comes directly from the study's public registry record.
Emilyn C Banfield · (240) 328-0965 · SCDtransfusionstudy@mail.nih.gov
Neil A Hanchard, M.D. · (301) 594-2151 · neil.hanchard@nih.gov
Always discuss trial participation with your own doctor first.
| National Institutes of Health Clinical Center | Bethesda, Maryland, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06944067